Meet the Evaluate Team: Andy Mills
If you work with Evaluate, you’ll probably be familiar with our delightful Customer Success team. They’re the people who help ensure that our customers can use our solutions to navigate the pharma landscape, and answer their key questions to help them make the right decisions about their business. One member of this team is Andy […]
Out-Licencing Strategies: How to Secure the Right Partner
When a biotech or biopharma’s flagship asset is ready for out-licensing, which strategies will get it noticed by the right partners? To gain the attention of larger players, companies need to present clear evidence of their asset’s efficacy and market potential, along with a realistic understanding of the types of deals they can secure. Leveraging […]
Five Steps to Refining Your In-Licencing Strategy
For pharma companies, biotech assets present significant opportunities to strengthen pipelines with reduced risk. However, with such a vast ecosystem, identifying the right assets that align with your strategy can be a challenge. Whether the dealmaking goal is a quick win in a major market or securing an innovative product early, finding the most valuable […]
Enhancing Competitive Intelligence in Biopharma: Key Strategies and Insights
In the ever-evolving landscape of biopharma and biotech, competitive intelligence (CI) plays a crucial role in driving strategic decisions and maintaining a competitive edge. At the recent Pharma CI conference in Newark, I had the pleasure of presenting to an audience of CI leaders to discuss ways of optimising the strategic value of cross-functional CI. […]
In Case You Missed It: Three Things we Learned in our Dealmaking Trends Webinar
If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore is dealmaking trends – and that’s just what my colleagues Ben Folwell and Duncan Sweeney did during our recent webinar, “Licence Drivers: Trends in Pharma […]
2024 Dealmaking: What’s the Score?
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s Pfizer/Seagen deal, though the Novo/Catalent deal aimed at boosting supplies of the semaglutide products Ozempic and Wegovy is certainly notable. Even so, the 18% increase […]
Meet the Team: Kelly Chamberlain
Kelly Chamberlain may not have been at the company very long, but that didn’t stop me swooping in to find out a little more about her. Kelly has joined Norstella, Evaluate’s parent company as Partner, Market Intelligence. She’s an expert in supporting competitive intelligence workflows and ensuring that CI teams can maximise the strategic value […]
In Case You Missed It: Three Things we Learned in our AI Forecasting Webinar
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re back, though, you’ll be delighted to know that it’s available on demand so you can catch up at your leisure. Our panel, which included Daniel […]
Unlocking the Power of AI in Pharmaceutical Forecasting
There is no shortage of discussion about the opportunities presented by artificial intelligence and AI in the pharma industry. 50% of global healthcare companies plan to implement AI strategies by next year and AI’s impact on new drug development is expected to grow 40% annually. There is no part of the pharmaceutical ecosystem that isn’t […]
In Case You Missed It: Three Things we Learned in our World Preview Webinar
Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of the future of this ever-changing market, from the biggest drugs and players, to the therapy areas in growth or decline. The report is excellent (not […]